Sanofi: Information Concerning the Total Number of Voting Rights and Shares - July 2024
FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment
Earnings Call: Novavax Q2 2024 Results Show Promise With Sanofi Deal
IDT Australia Receives New Contract From Sanofi Australia; Shares Up 9%
COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit
Sanofi's Approved Blood Cancer Drug Sarclisa Shows Improved Progression-Free Survival In Patients Eligible For Transplant
Novavax Drops After Q2 Miss and Guidance Cut
Bernstein: Sanofi Set to Record Growth on Expected Multiple Sclerosis Boost
Express News | Recursion Pharmaceuticals to Acquire Exscientia for $688 Million
Iron Drugs Industry Forecast Report, 2028: Includes Strategic Analyses of McKesson, Sanofi, GlaxoSmithKline (GSK), Rockwell Medical, Shield Therapeutics, and Pharmacosmos
Sanofi : Sarclisa Induction Treatment Improves PFS In Transplant-Eligible Myeloma Patients
Sanofi's Blood Cancer Combo Extends Progression-free Survival in Late-stage Study
New Drugs and Cost Controls Fuel Wave of Pharma Guidance Lifts -- Analysis
European Exporters With Stretched Valuations - JPM
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
Latest update on Zantac carcinogenic lawsuit: glaxosmithkline (GSK.US) wins in the latest trial.
United Kingdom pharmaceutical company GlaxoSmithKline (GSK.US) has convinced an Illinois jury that the pre-heartburn drug Zantac was not responsible for a woman's colon cancer and has won the second trial.
The Zacks Analyst Blog AstraZeneca, Ionis and Sanofi
Healey-Driscoll Administration Awards $500k to Wentworth Institute of Technology
European stocks show their worst performance in more than a year as weak US data intensifies sell-offs.
European stock markets continued to fall due to weaker-than-expected US employment data, intensifying market concerns about economic growth, which led to a further drop in technology stocks. The STOXX 600 index fell 2.7%, the biggest drop in over a year. Investors sought refuge in defensive sectors, with utilities and some pharmaceutical stocks performing well, including AstraZeneca and Sanofi. The technology sector led the decline, with the technology sub-index falling 6.1%, the biggest drop since October 2020. Before the release of US employment data, this sector had already experienced a decline, and Intel's plans to cut capital expenditures put heavy pressure on similar European sectors. Silver.
Vir Bio Trims Staff and Pipeline to Focus on Sanofi-licensed Programmes